Novavax, Inc.

NASDAQ:NVAX

Biotechnology

Healthcare
$7.96 -1.84%

-$0.18 today

Market cap
$1.31B
Beta
2.41
P/E (TTM)
-17.3
EPS (TTM)
-$0.54
52W Low $6.13High $11.97

Volume 4.24M

Average 4.58M

NVAX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Novavax, Inc.NASDAQ: NVAX

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables growth accelerates

Q1 FY2026 accounts receivables of $86.24M rose 16.8% year over year, ahead of the -44.3% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -37.4% a year.

Context

  • Accounts receivables amounted to 5.4% of revenue in FY2025, down 46.5 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +16.8% holds above the trailing-twelve-month pace of -44.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$86.24M+266.0% QoQ
Last fiscal yearDec 2025
$61.04M-82.8% YoY
LTMMar 2026
$73.42M-44.3% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.8%——
1 year-82.8%——
3-year CAGR-37.4%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
61.04M USD
Year-over-year change
-82.8%

Accounts Receivables vs competitors

How NVAX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -44.3% is the 5th highest of 7, against a peer median of +53.3%.
  • Accounts receivables amounts to 12.3% of revenue for NVAX, versus a peer median of 12.9%.
NVAX Competitors
Accounts Receivables for NVAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€1.89B EUR+210.6%-38.0%71.6%
MRNAModerna, Inc.LTM Sep 2026$325M USD-164.6%-55.7%12.9%
NVAXNovavax, Inc.LTM Mar 2026$73.42M USD-44.3%-37.4%12.3%
EBSEmergent BioSolutions Inc.LTM Mar 2026$59.9M USD+225.6%-40.0%8.9%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$13.31M USD+6.6%—29.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$331.65K USD-73.3%——
PCVXVaxcyte, Inc.LTM Jun 2026$0 USD———
VALNValneva SELTM Mar 2026€0 EUR+100.0%+2.4%0.0%
Peer median (excluding NVAX) —+53.3%-39.0%12.9%

Competitors are the stored peer set for NVAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.74B)(657.94M)(545.06M)(187.5M)440.3M
Depreciation & Amortization12.66M29.05M41.23M48.5M27.61M
Deferred Income Tax00000
Stock-Based Compensation183.63M130.3M85.36M48.15M36.02M
Change in Working Capital1.73B(361.15M)(376.84M)48.48M(887.71M)
Accounts Receivables(192.27M)249.17M(274.44M)354.09M61.04M
Inventory(600.33M)(477.8M)(74.46M)12.91M(3.24M)
Accounts Payables600.33M913.4M(378.81M)(385.63M)(322.57M)
Other Working Capital1.93B(1.05B)350.87M67.11M(622.94M)
Other Non-Cash Items136.79M443.8M81.35M(44.89M)139.14M
Operating Cash Flow322.95M(415.94M)(713.97M)(87.26M)(244.64M)
Capital Expenditures(57.49M)(92.99M)(58.81M)(13.06M)(5.56M)
Acquisitions (Net)57.49M00192.64M0
Purchases of Investments(2.17M)00(825.59M)(445.27M)
Sales of Investments159.81M00443.55M353.74M
Other Investing Activities(57.49M)00018.83M
Investing Cash Flow100.15M(92.99M)(58.81M)(204.04M)(78.27M)
Debt Repayment(127.91M)81.66M(352.35M)(3.99M)32.53M
Common Stock Issued564.86M249.23M360.24M263.27M0
Common Stock Repurchased0000(4.8M)
Dividends Paid00000
Other Financing Activities24.76M(5.9M)(3.59M)1.31M0
Financing Cash Flow461.71M324.99M4.47M260.58M27.74M
Effect of Forex Changes(5.29M)4.52M3.27M(7.8M)5.93M
Net Change in Cash879.52M(179.41M)(765.04M)(38.52M)(289.24M)
Free Cash Flow265.46M(508.92M)(772.77M)(100.32M)(250.2M)

Novavax, Inc.

NASDAQ:NVAX

Intrinsic Alpha fair value

Locked

Current Price

$7.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.